Fortis Healthcare Limited, one of India's leading integrated healthcare delivery service providers, has announced strong financial results for the first quarter of fiscal year 2026, demonstrating significant growth across key metrics.

Financial Highlights

Fortis Healthcare reported consolidated revenues of INR 2,167.00 crore for Q1 FY26, marking a substantial 16.6% increase from INR 1,859.00 crore in the same quarter last year. The company's operating EBITDA saw an impressive surge of 43.2%, reaching INR 491.00 crore compared to INR 343.00 crore in Q1 FY25. The operating EBITDA margin expanded to 22.6% from 18.4% year-over-year, indicating improved operational efficiency.

The company's profit after tax (PAT) after minority interest and share in associates grew by 56.8% to INR 260.00 crore, up from INR 166.00 crore in the corresponding quarter of the previous year. Consequently, earnings per share (EPS) improved to INR 3.45 from INR 2.20.

Hospital Business Performance

The hospital business, a key driver of Fortis Healthcare's growth, reported revenues of INR 1,838.00 crore, an 18.6% increase from INR 1,549.00 crore in Q1 FY25. The segment's operating EBITDA stood at INR 406.00 crore, up 41.4% year-over-year, with the operating EBITDA margin improving to 22.1% from 18.5%.

Key performance indicators for the hospital business showed positive trends:

• Occupancy increased to 69% from 67% in Q1 FY25
• Average Revenue Per Occupied Bed (ARPOB) rose by 10.2% to INR 2.65 crore per annum
• International patient revenues grew by 21% to INR 154.00 crore, contributing 7.9% to overall hospital business revenues

Diagnostics Business Growth

Fortis Healthcare's diagnostics arm, Agilus, also demonstrated strong performance. The segment's gross revenues grew by 7.4% to INR 368.80 crore in Q1 FY26. Operating EBITDA margin (based on gross revenues) improved significantly to 23.0% from 16.1% in Q1 FY25.

During the quarter, Agilus conducted 10.13 million tests, representing a 5.8% increase from the 9.57 million tests in Q1 FY25. The company continued its network expansion, adding over 160 new customer touchpoints.

Strategic Developments

Fortis Healthcare announced two significant strategic moves during the quarter:

1. The company entered into an Operation and Maintenance Services agreement with Gleneagles India, expanding its footprint in key metro cities. Under this agreement, Fortis will manage operations of approximately 700 beds across five hospitals and a clinic within the Gleneagles India network.

2. Fortis consummated the acquisition of Shrimann Superspecialty Hospital in Jalandhar, Punjab, adding 228 beds to its network and strengthening its presence in the Punjab region to approximately 1,000 beds.

Management Commentary

Dr. Ashutosh Raghuvanshi, MD and CEO of Fortis Healthcare, commented on the results, stating, "We have witnessed a healthy start to the financial year, as demonstrated in our Q1 earnings for both hospital and diagnostic businesses. The recently executed O&M services agreement with Gleneagles India expands our geographic footprint and provides an opportunity to leverage our combined strengths to optimize operations and enhance efficiencies."

He further added, "In the diagnostics business, we have witnessed a strong recovery in both revenues and EBITDA margins, which is reflective of the brand building initiatives undertaken over the last few quarters. We expect this growth momentum to continue going forward."

The robust Q1 FY26 results underscore Fortis Healthcare's strong market position and effective growth strategies in both its hospital and diagnostics segments. With strategic expansions and operational improvements, the company appears well-positioned for continued growth in the Indian healthcare sector.

Fortis Healthcare Limited announced a significant expansion in its healthcare portfolio as its wholly-owned subsidiary, Fortis Hospotel Limited (FHTL), successfully completed the acquisition of Shrimann Superspecialty Hospital's entire business operations. The transaction, which includes the hospital land and adjacent property, was finalized on July 24, 2025, at 09:14 PM IST.

Acquisition Details

The completion of this acquisition marks a crucial milestone for Fortis Healthcare, following a series of strategic moves earlier in the year. The company had previously disclosed information about the transaction through intimations to the stock exchanges in February, March, and May 2025, detailing the definitive agreements for this significant acquisition.

Regulatory Compliance

In compliance with Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015, Fortis Healthcare Limited promptly informed the National Stock Exchange of India Ltd. and BSE Limited about the successful consummation of the transaction. The disclosure was made through an official letter signed by Satyendra Chauhan, the Company Secretary & Compliance Officer of Fortis Healthcare Limited.

Strategic Implications

This acquisition is expected to strengthen Fortis Healthcare's market position and expand its healthcare services portfolio. By incorporating Shrimann Superspecialty Hospital's operations and assets, Fortis is poised to enhance its capabilities in specialized medical care and potentially increase its market share in the region.

Looking Ahead

While specific financial details of the transaction were not disclosed in the announcement, the acquisition of an entire hospital operation, including land and property, suggests a significant investment by Fortis Healthcare. This move aligns with the company's growth strategy and may lead to expanded service offerings and increased patient capacity in the future.

Investors and stakeholders will likely be watching closely to see how this acquisition impacts Fortis Healthcare's operational performance and market presence in the coming quarters.